Home > Publications Database > Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum. > print

001     163503
005     20240826165945.0
024 7 _ |a 10.3233/JAD-215196
|2 doi
024 7 _ |a pmid:34924387
|2 pmid
024 7 _ |a 1387-2877
|2 ISSN
024 7 _ |a 1875-8908
|2 ISSN
024 7 _ |a altmetric:119464879
|2 altmetric
037 _ _ |a DZNE-2022-00263
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 0
|e First author
245 _ _ |a Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum.
260 _ _ |a Amsterdam
|c 2022
|b IOS Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1710930649_2063
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Inflammation has been described as a key pathogenic event in Alzheimer's disease (AD), downstream of amyloid and tau pathology. Preclinical and clinical data suggest that the cholinergic basal forebrain may moderate inflammatory response to different pathologies.To study the association of cholinergic basal forebrain volume and functional connectivity with measures of neuroinflammation in people from the AD spectrum.We studied 261 cases from the DELCODE cohort, including people with subjective cognitive decline, mild cognitive impairment, AD dementia, first degree relatives, and healthy controls. Using Bayesian ANCOVA, we tested associations of MRI indices of cholinergic basal forebrain volume and functional connectivity with cerebrospinal fluid (CSF) levels of sTREM2 as a marker of microglia activation, and serum levels of complement C3. Using Bayesian elastic net regression, we determined associations between basal forebrain measures and a large inflammation marker panel from CSF and serum.We found anecdotal to moderate evidence in favor of the absence of an effect of basal forebrain volume and functional connectivity on CSF sTREM2 and serum C3 levels both in Aβ42/ptau-positive and negative cases. Bayesian elastic net regression identified several CSF and serum markers of inflammation that were associated with basal forebrain volume and functional connectivity. The effect sizes were moderate to small.Our data-driven analyses generate the hypothesis that cholinergic basal forebrain may be involved in the neuroinflammation response to Aβ42 and phospho-tau pathology in people from the AD spectrum. This hypothesis needs to be tested in independent samples.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 1
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 2
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a MRI
|2 Other
650 _ 7 |a cerebrospinal fluid
|2 Other
650 _ 7 |a cholinergic system
|2 Other
650 _ 7 |a neuroinflammation
|2 Other
650 _ 7 |a plasma
|2 Other
650 _ 7 |a sTREM2
|2 Other
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Cholinergic Agents
|2 NLM Chemicals
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Alzheimer Disease: pathology
|2 MeSH
650 _ 2 |a Basal Forebrain: pathology
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Cholinergic Agents
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: pathology
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Inflammation: pathology
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Male
|2 MeSH
693 _ _ |0 EXP:(DE-2719)DELCODE-20140101
|5 EXP:(DE-2719)DELCODE-20140101
|e Longitudinal Cognitive Impairment and Dementia Study
|x 0
700 1 _ |a Dyrba, Martin
|0 P:(DE-2719)2810283
|b 1
700 1 _ |a Ballarini, Tommaso
|0 P:(DE-2719)9000476
|b 2
700 1 _ |a Brosseron, Frederic
|0 P:(DE-2719)2810593
|b 3
700 1 _ |a Bruno, Davide
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Bürger, Katharina
|0 P:(DE-2719)2811351
|b 5
|u dzne
700 1 _ |a Cosma, Nicoleta-Carmen
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Dechent, Peter
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Dobisch, Laura
|0 P:(DE-2719)2811611
|b 8
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 9
700 1 _ |a Ewers, Michael
|0 P:(DE-2719)9000543
|b 10
700 1 _ |a Fliessbach, Klaus
|0 P:(DE-2719)2811326
|b 11
700 1 _ |a Haynes, John D
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Janowitz, Daniel
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Kilimann, Ingo
|0 P:(DE-2719)2810394
|b 14
700 1 _ |a Laske, Christoph
|0 P:(DE-2719)2000055
|b 15
700 1 _ |a Maier, Franziska
|0 P:(DE-HGF)0
|b 16
700 1 _ |a Metzger, Coraline D
|0 P:(DE-2719)9000443
|b 17
700 1 _ |a Munk, Matthias H
|0 P:(DE-2719)9001516
|b 18
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 19
700 1 _ |a Pomara, Nunzio
|0 P:(DE-HGF)0
|b 20
700 1 _ |a Preis, Lukas
|0 P:(DE-2719)9000703
|b 21
700 1 _ |a Priller, Josef
|0 P:(DE-2719)2811122
|b 22
700 1 _ |a Ramírez, Alfredo
|0 P:(DE-2719)2812825
|b 23
700 1 _ |a Roy, Nina
|0 P:(DE-2719)2812341
|b 24
700 1 _ |a Scheffler, Klaus
|0 P:(DE-HGF)0
|b 25
700 1 _ |a Schneider, Anja
|0 P:(DE-2719)2812035
|b 26
700 1 _ |a Schott, Björn H
|0 P:(DE-2719)2814326
|b 27
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 28
700 1 _ |a Spruth, Eike J
|0 P:(DE-2719)2812446
|b 29
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 30
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 31
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 32
700 1 _ |a Heneka, Michael T
|0 P:(DE-2719)2000008
|b 33
|e Last author
773 _ _ |a 10.3233/JAD-215196
|g Vol. 85, no. 3, p. 1267 - 1282
|0 PERI:(DE-600)2070772-1
|n 3
|p 1267 - 1282
|t Journal of Alzheimer's disease
|v 85
|y 2022
|x 1875-8908
856 4 _ |u https://pub.dzne.de/record/163503/files/DZNE-2022-00263_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/163503/files/DZNE-2022-00263_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:163503
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2000026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810283
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9000476
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2810593
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2811351
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2811611
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2000005
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)9000543
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2811326
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2810394
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)2000055
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)9000443
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 18
|6 P:(DE-2719)9001516
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)2811024
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 21
|6 P:(DE-2719)9000703
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 22
|6 P:(DE-2719)2811122
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 23
|6 P:(DE-2719)2812825
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2812341
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 26
|6 P:(DE-2719)2812035
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 27
|6 P:(DE-2719)2814326
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 28
|6 P:(DE-2719)2811324
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 29
|6 P:(DE-2719)2812446
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 30
|6 P:(DE-2719)2000057
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 31
|6 P:(DE-2719)2811317
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 32
|6 P:(DE-2719)2000032
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 33
|6 P:(DE-2719)2000008
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 1
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 2
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J ALZHEIMERS DIS : 2021
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-18
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-18
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 0
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 1
920 1 _ |0 I:(DE-2719)1011301
|k Biomarker
|l Interventional Trials and Biomarkers in Neurodegenerative Diseases
|x 2
920 1 _ |0 I:(DE-2719)1340009
|k AG Speck
|l Linking imaging projects iNET
|x 3
920 1 _ |0 I:(DE-2719)1110008
|k AG Simons
|l Molecular Neurobiology
|x 4
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies Bonn
|l Patient Studies Bonn
|x 5
920 1 _ |0 I:(DE-2719)1240005
|k Core ICRU
|l Core ICRU
|x 6
920 1 _ |0 I:(DE-2719)6000015
|k Magdeburg common
|l Magdeburg common
|x 7
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 8
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Interdisciplinary Dementia Research
|x 9
920 1 _ |0 I:(DE-2719)5000007
|k AG Priller
|l Translational Neuropsychiatry
|x 10
920 1 _ |0 I:(DE-2719)1011401
|k Clinical Research Platform (CRP)
|l Clinical Research Platform (CRP)
|x 11
920 1 _ |0 I:(DE-2719)1011305
|k AG Schneider
|l Translational Dementia Research (Bonn)
|x 12
920 1 _ |0 I:(DE-2719)1410002
|k AG Fischer
|l Epigenetics and Systems Medicine in Neurodegenerative Diseases
|x 13
920 1 _ |0 I:(DE-2719)1011001
|k AG Klockgether
|l Patient Studies
|x 14
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases
|x 15
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 16
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 17
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 18
920 1 _ |0 I:(DE-2719)5000034
|k Delcode
|l Delcode
|x 19
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1011201
980 _ _ |a I:(DE-2719)1011301
980 _ _ |a I:(DE-2719)1340009
980 _ _ |a I:(DE-2719)1110008
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a I:(DE-2719)1240005
980 _ _ |a I:(DE-2719)6000015
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)1811005
980 _ _ |a I:(DE-2719)5000007
980 _ _ |a I:(DE-2719)1011401
980 _ _ |a I:(DE-2719)1011305
980 _ _ |a I:(DE-2719)1410002
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)1410006
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a I:(DE-2719)5000022
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)5000034
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21